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ABSTRACT
Low bone density for age is becoming an increasingly recognized problem in the
pediatric world. It can be a very tricky condition to properly diagnose and treat. Current
treatment guidelines maintain that bisphosphonates are a last resort therapy and are not
currently FDA approved for pediatric use. There is data available that supports the use of
these agents in children for the treatment of low bone density, as well as secondary
benefits, i.e. decreased incidence of insufficiency fractures. However, the majority of the
studies includes small population sizes, they are not randomized, or are not compared to a
control group. There is clearly a need for further investigation. METHODS: 36 patients
from the Carrie Tingley Bone Health Center were included as treatment subjects
(received IV and/or PO bisphosphonates) in this retrospective review of pre and posttreatment Dual-Energy X-Ray Absorptiometry (DXA) scans. They were compared to a
control group of 30 patients, also with low bone mineral density. Statistical comparison
of the differences of bone mineral density, g/cm2, of each region scanned was done with
the Mann-Whitney test. RESULTS: A statistically significant improvement over the
control group was found in the lumbar region of patient’s receiving treatment. Mean
improvement for the lumbar region of the treatment group was 0.091 g/cm2, compared to
0.032 g/cm2 for the control group; P-value of 0.03. Average treatment length is 14.5
months, (range 0.5 to 53). The treatment group also demonstrated an 88% decrease in the
occurrence of fractures, as well as an average 17% improvement in the R1 region of the
distal femur. CONCLUSIONS: Bisphosphonate therapy led to a statistically significant
improvement in BMD in the lumbar region and potentially decreases the rate of fractures.
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INTRODUCTION
Low bone density for age is becoming an increasingly recognized problem in the
pediatric world. It can be a very tricky condition to properly diagnose and treat. It is
generally considered an adult disease, but there is increasing evidence that its roots lie in
childhood [3]. As Dr. Laura Bachrach states, “the foundation for lifetime skeletal health
is established during childhood and adolescence [4].” Low bone density for age is
defined as a DXA scan resulting in a z-score less than -2.0 SD from age and gender
matched norms [2,3,15]. Pediatric osteoporosis is not defined the same as adult
osteoporosis, it not only includes the definition of low bone density for age but also
requires additional evidence of bone fragility such as an insufficiency fracture or fragility
fracture. A fragility fracture is a fracture obtained from minimal trauma [15]. Most
children, and certainly our study population, who suffer from these problems are
suffering from a chronic illness and in many cases are severely debilitated.
The maintenance of bone is a dynamic process between rate of formation and
resorption. During childhood and adolescence the process of formation predominates and
leads to a net increase in bone mass and size [3]. Our peak bone mass is achieved in
early adulthood, sometime during the third decade [2,3,4,10]. After this peak, bone mass
(in an otherwise healthy individual) begins to slowly decline over the years. The rate of
decline is typically constant for males and females, therefore the more bone mass a
person is able to achieve earlier in life will help to lower the risk of future complications
[4,8]. A potentially encouraging aspect to low bone density and bone loss in an adult is
that it may have started as a failure to achieve optimal peak bone density, and this is a
significant and preventable problem. Maintaining a healthy bone density and optimizing
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your peak bone density is dependent upon both intrinsic and extrinsic factors. The
intrinsic factors are unmodifiable and include genetic background, race and ethnicity, and
gender [3]. The extrinsic factors are of particular importance because they are
modifiable. The extrinsic factors include the following: physical activity, adiposity,
diet/nutritional status, hormonal status, illness, medication exposures, excessive alcohol
intake, and smoking [3,4,8,10].
Low bone density for age and pediatric osteoporosis has numerous etiologies. The
children presented here are not all suffering low bone density from the same cause.
Furthermore, despite the numerous illnesses associated with low bone density, not all
etiologies share the same reason for their low bone density. Finding low bone density in
a child does not tell you if the bone loss is accelerated or if the density is low due to a
failure to gain the expected bone mineral density [14]. This difference in mechanisms
has the potential to determine the therapy needed to properly treat the low bone density.
The population used in this study is comprised of children who are suffering from
a chronic illness that in many cases is very debilitating. The more common etiologies of
low bone density for age in our study population are associated with the following
disorders: cerebral palsy, corticosteroid therapy, and anticonvulsant therapy. Each of
these etiologies in our population has lead to low bone density by a particular
mechanism. For example, cerebral palsy patients tend to suffer from low bone density if
they are non-ambulatory. Ambulation is necessary for bone health and strength. It is the
bearing of ones body weight on the skeleton that improves bone strength [2]. Children on
corticosteroids, for various reasons including autoimmune disorders and
immunosuppression, suffer low bone density as a side effect of this therapy and the drugs
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overall catabolic effects [2,3]. Patients who take anticonvulsants or require multi-agent
therapy for seizure control also suffer low bone density because the anticonvulsants will
increase the metabolism of vitamin D [2,10], this in effect hinders its ability to increase
intestinal calcium absorption and bone formation as a whole is decreased [7].
Calcium and Vitamin D are of extreme importance in the cause and treatment of
patients suffering from low bone density. Calcium and Vitamin D play important roles in
bone formation [3,7]. Calcium is necessary to maximize and maintain peak bone mass
and to minimize bone loss during aging, therefore optimal intake is necessary [3].
Further increasing the demand for calcium are periods of rapid growth, such as infancy
and adolescence [3]. Retrospective studies have shown that adequate calcium intake
during childhood and adolescence was associated with a lower incidence of osteoporosis
in postmenopausal women [3]. Unfortunately, similar data is unavailable for children
and adolescents [2]. Nevertheless, adequate intakes of calcium and vitamin D should be
provided [2]. Vitamin D is crucial for the effectiveness of calcium and its deficiency can
certainly be a cause of low bone density. It is recommended that patients be treated with
both calcium and vitamin D simultaneously [3,10]. Vitamin D supplementation may also
be most effective for certain etiologies of low bone density [2]. Studies suggest that
calcium and vitamin D supplements are an excellent place to start when treating low bone
density, and additional medications should be started only when bone density does not
improve on calcium and vitamin D supplementation [5].
Bisphosphonates are anti-resorptive agents used to treat low bone density in
adults. Currently they are not FDA approved for pediatric use. Their mechanism of
action is not completely elucidated but they reduce bone turnover by decreasing bone
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resorption. They directly decrease the recruitment and function of osteoclasts and
indirectly inhibit osteoclasts by stimulating osteoblasts to produce an inhibitor of
osteoclast formation [2]. There is an unfortunate lack of research involving use of
bisphosphonates in pediatric cases [2,13,14], most involved a very small population size
and were poorly controlled. Nonetheless, small studies have shown encouraging results
with the use of bisphosphonates in children. Other studies have shown that low-dose
pamidronate can result in increased bone mineral density in children with a variety of
conditions (including: osteogenesis imperfecta, corticosteroird therapy, idiopathic
juvenile osteoporosis) [14]. This data has been considered “pilot data” and the need for
additional studies has been emphasized [13,14]. The current treatment for low bone
density in the pediatric population is supplementation with calcium, vitamin D and/or
bisphosphonates, however sufficient data to prove efficacy is lacking.
One study in particular, by Henderson, et. al., [1], looked at the use of
bisphosphonates in children with cerebral palsy. The results of this study are very
encouraging as they demonstrate an improvement in bone mineral density (BMD) of 89%
in the distal metaphyseal femur. His study group is small, but is randomized to include a
control group. A control group is an important feature that needs to be taken into account
with the pediatric population. Growing children are moving targets, so evaluating their
bone mineral density requires that normal growth be accounted for; unfortunately there is
an overall lack of data (other than case studies and small population sizes) that truly show
an improvement [3,13]. Against comparison to a control group, we too have
demonstrated improved BMD with IV or PO bisphosphonate therapy.
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METHODS
Approval was obtained from the University’s internal review board to conduct a
retrospective review of available data where both a pretreatment bone density scan and a
post-treatment, follow up scan is performed. The subject population is the pediatric
population at the Carrie Tingley Hospital (CTH) who have undergone Dual-Energy XRay Absorptiometry (DXA) scanning for clinical reasons, and whose scans indicated low
bone density based on age matched databases used for the DXA scanning. Scans were
performed between 2003 and 2008. Those included have had both their pretreatment and
follow up scan performed at the Carrie Tingley Bone Health Center. Furthermore, the
patients included were only those who consented to have their data used in research. All
scans were performed by a certified DXA technologist using a Hologic Delphi W
densitometer (Hologic, Inc, Bedford, MA) using pediatric software for the spine, hip
(based on publications of Faulkner and Southard) and lateral distal femoral scan. The
distal femoral scans include three regions: R1 – cancellous bone, R2 – mixed cancellous
and cortical bone, and R3 – cortical bone. To ensure consistency between DXA scans the
same machine was used for the pre and post scans.
Data was extracted from the dictated report and included the patient’s past
medical history, past surgical history, current medications, supplementation, ambulatory
status, fracture history and of course, the bone densities of the various regions scanned.
Similarly, data for a control group was established. The control group patients met the
same inclusion criteria as the treatment group. Efforts were made to form a control group
of patients whose primary medical conditions mirrored those of the treatment group.
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Again, patients eligible for inclusion in the control group were those who consented for
their data to be used in research.
A comparison of each region scanned was done and the difference in bone
mineral density between the pretreatment and post treatment scan was recorded. The
difference reflects the changes in bone mineral density, g/cm2, over the interval. This
was done for all regions scanned. It was the difference of each region that underwent
statistical analysis.
Summary statistics were calculated using standard methods. Mean bone mineral
density values were compared for treatment and non-treatment groups using the MannWhitney test. All calculations were performed on an Intel Pentium-based microcomputer
with a clock speed of 1.8 GHz. Statistical calculations were made with Statgraphics
Centurion XV version 15.2.06 (StatPoint, Inc., Herndon, VA). Data management was
carried out using Microsoft Excel 2002 (Microsoft Corporation, Redmond, WA). Two
tailed tests and a Type I error rate of 0.05 were employed throughout.

RESULTS
Forty-three patients were identified as candidates for inclusion in the treatment
group. At the end of the study period there were 36 patients with data available for
analysis. Of the initial 43 identified, 4 patients who received treatment did not have a
follow-up scan available. Two patients did not have the correct medical record number
recorded and their data was unable to be retrieved. One patient’s record was too unclear
to determine a treatment period and was thought to be too unreliable for inclusion. The
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control group is made up of 30 patients who were identified to have low bone mineral
density and similar medical histories as those comprising the treatment group.
The patient’s included in the treatment group have the following characteristics.
The average age of the patients is 11.9 years old, with a range from 2yrs to 21years old.
The average treatment length is 14.5 months, with a range from 0.5 to 53 months. The
average interval between DXA scans is 16 months, with a range from 4 to 42 months.
The bisphosphonate therapy received was either alendronate (PO) or pamidronate (IV).
Twenty-seven patients received solely alendronate therapy, 5 patient’s received only
pamidronate therapy, 3 patient’s began alendronate therapy and were switched to
pamidronate therapy and 1 patient was begun on pamidronate therapy and switched to
alendronate. The control group has an average age of 9.2 years old, with a range from 1
to 16 years old. The average interval between DXA scans for the control group is 17.9
months, with a range from 6 to 44 months. Please see Table 1 for a more in depth
comparison of the treatment and control groups.
The most common medical conditions found in the patients comprising the
treatment group are cerebral palsy with a seizure disorder and osteogenesis imperfecta
and other dysplastic syndromes. For the control group, the most common medical
conditions for these patients are cerebral palsy with seizure disorder and long-term
corticosteroid therapy and malignancy. Please see Table 2 for a comparison of the
patient’s medical histories.
Results of the comparison of the difference in bone mineral density, g/cm2, of the
multiple regions scanned yields the following result. The only region of the treatment
group found to have a statistically significant improvement over that of the control group,
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was the lumbar region. Mean improvement (difference of BMD in pre/post scan) for the
lumbar region of the treatment group was 0.091 g/cm2, compared to 0.032 g/cm2 for the
control group; P-value of 0.03. The remaining regions compared did not demonstrate any
statistically significant improvements in BMD in the treatment group compared to the
improvements made by the control group. Please see Table 3 for a summary of the mean
improvements of each region. Table 3 also presents the average percent change for each
region scanned for both groups. This calculation is a straight average of all the results
available in each group for each region. The percent change was not used in any
statistical analysis.

DISCUSSION
It has been found that the most useful regions for interpretation on pediatric DXA
scans are the distal femora and the lumbar region [15]. As the results to this study would
indicate, there was a statistically significant improvement in the lumbar region of the
treatment group. This would suggest that bisphosphonate treatment was of benefit to
these patients; that the improvement seen was more than expected for bone mineral
density increases related to normal growth. This is established by the comparison to the
control group, a group of children with similar medical histories, but whose increases in
bone mineral density are best explained by growth. An important point of discussion is
necessary for this result. The number of patients in the control group who were receiving
long-term corticosteroid therapy was much greater than that of the treatment group, (4
patients in the treatment group versus 11 in the control group). This is important because
the decreases in bone mineral density associated with corticosteroids are most
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pronounced in the spine. This makes true interpretation of the results more difficult, as it
is possible the improvement the treatment group demonstrated was confounded by the
expected losses in the lumbar regions of a high percentage of the control group.
Although none of the other regions studied may have shown statistically
significant improvements, that might suggest more BMD was gained than expected for
growth, there is evidence that would still support the use of these agents in the pediatric
population. If the average percent changes were looked at for each region, with specific
focus on the distal femora, the treatment group experienced greater changes almost across
the board. This too is hard to definitively say if normal growth or intervention is the
primary cause of improvement. When bisphosphonates are used it is evidenced by the
presence of a “bisphosphonate stripe” in the DXA scan [15]. Most commonly seen in the
R1 region of the distal femur[15]. The scans of the vast majority of the patient’s did
comment on the presence of this strip. This is also seen by the large percent
improvement of the R1 region alone, combined left and right of 17.4% versus 1.1% in the
control. The R2 and R3 regions also show higher percent changes, but not to the same
significance. This leads me to believe that the improvements seen in the patients who
received therapy were not due to normal growth alone, but are a direct effect of
bisphosphonate therapy.
In the treatment group, review of the patient’s record demonstrated that the two
main indications for initiation of bisphosphonate therapy are, (1) the history of
insufficiency fractures or (2) the patient has had serial scans demonstrating a loss of bone
mineral density. Generally, the loss was significant enough to place the patient at great
risk of fragility fractures. This history suggests that many of the patients were not staying
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with a normal growth curve, demonstrated in the reports by worsening z-scores. With the
results indicating overall improvement in the BMD of the patients on therapy, it would be
favored that the bisphosphonates were in part responsible.
Another important variable in the characteristics of the treatment versus the
control group is the ambulatory status of the patients. The majority, 56%, of the
treatment group is non-ambulatory. This has profound influence on a person’s BMD, as
weight-bearing activity promotes increased BMD. The control group is 63% ambulatory,
almost double that of the treatment group (36.1% ambulatory). This important difference
could potentially minimize the observed effect of bisphosphonate therapy in a larger nonambulatory population.
Limitations to the study include a restricted patient population available for study,
the retrospective chart review format, and the reliance on patient recall, mainly patient
caregiver recall, for some of the data obtained. The limited study population for both
groups stems from the inclusion of only “Blue Star” patients, again that is those who
consented to have their data used in research. A larger treatment group certainly exists at
Carrie Tingley Hospital. The retrospective nature of the study did not allow active
pursuit of patient compliance with treatment and follow-up DXA scanning. The patient’s
caregiver recall of medications and supplementations is another area were inherent
limitations exist. For example, the data on those receiving calcium and/or vitamin D
supplementation was recorded from the DXA report, which reflects the patient survey
done prior to the scan. The majority of patients simply stated, “yes/no” or left the section
blank. This made it impossible to know frequency and dosing of these supplements. If
the section was left blank, it was assumed that no supplementation was being given. Best
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efforts were made to identify true treatment intervals by reviewing the patient’s
medication histories and review of primary care physician notes.
Furthermore, there was no randomization to who received treatment or at what
dosing. The dose of the bisphosphonate was determined by the treating physician and
was generally weight based and different for all subjects. The only consistency was the
use of a 1ml/kg dosing of the IV pamidronate therapy.
One important result discovered that could be a result of the bisphosphonate
therapy was the incidence of fractures in the treatment patients, both before and after
receiving therapy. There is a study done by Sholas, et al., [17] that also supports this
conclusion, as his data demonstrates that those who received oral alendronate therapy
displayed a decrease rate of fractures after receiving the therapy. Twenty-nine of 36
patients had a fracture history prior to starting bisphosphonate therapy. Of these 29
patients, 25 of them were classified as pathologic, insufficiency fractures. This was
obtained also from the patient’s DXA report and other clinic notes. After receiving
therapy, 3 patients were noted to have experienced further fractures over the interval
studied. One of the patients was then changed from PO to IV therapy, but it is unknown
if any further fractures were suffered. This demonstrates that 88% of patients who
received treatment did not suffer further pathologic fractures. This is important, as it
would lead to an improved quality of life for the patient.
The results to this study are not without clinical implications. Despite the fact
that a statistically significant improvement was not seen in all regions studied, secondary
measures would suggest usefulness in this population. The results demonstrate a benefit
on reduction of the rate of fractures these patients are experiencing. As stated previously,
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one of the current reasons to begin bisphosphonate therapy is a history of insufficiency
fractures. Bisphosphonate therapy appears to work to prevent future fractures. However,
further investigation on the efficacy is needed, especially with larger study populations.
Studying these agents in a more controlled environment, i.e. one where compliance and
medication administration is optimized and reliable, as well as optimization of calcium
and vitamin D administration. Comparatively, a low percentage of the treatment group
was receiving calcium and vitamin D supplementation. Calcium supplementation was
reported in 56% of the treatment group versus 70% of control group. Vitamin D
supplementation was reported in 3% of the treatment group versus 27% of the control.
The magnitude of the affect this difference has made on the results of this study is
uncertain. Nevertheless, bisphosphonate use in the pediatric population can provide
important quality of life outcomes, with demonstrated improvements in bone mineral
density.

ACKNOWLEDGMENTS
Special thanks would like to be made to the following individuals for their assistance in
the completion of this study. Jude McMullan, Administrative Assistant to Dr. Szalay, for
her help in identifying patients and day-to-day trouble shooting. Also to Dr. Dan
Tandberg, professor emeritus in the Department of Emergency Medicine, for his help
with the statistical analysis of the results.

Page 14 of 18

Loucks
REFERENCES

1. Henderson, Richard C., et al. Bisphosphonates to treat osteopenia in children with
quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial. Journal of
Pediatrics 2002 Nov; 141 (5).
2. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Osteoporosis in Children and
Adolescents: Etiology and Management. Pediatric Drugs 2005: 7 (5); 295-323.
3. Steelman J, Zeitler P. Osteoporosis in Pediatrics. Pediatrics in Review 2001; 22 (2):
56-65.
4. Bachrach, Laura K. Osteoporosis and Measurement of Bone Mass in Children and
Adolescents. Endocrinology and Metabolism Clinics of North America 2005; 34: 521535.
5. Horlick, Mary, et al. Prediction Models for Evaluation for Total-body bone Mass
With Dual-Energy X-Ray Absorptiometry Among Children and Adolescents.
PEDIATRICS 2004 Sept; 114 (3): 337-345.
6. Ellis, KJ et al. Z score prediction model for assessment of bone mineral content in
pediatric diseases. J Bone Miner Res 2001 Sept; 16 (9): 1658-64.
7. Chesney, Russell W. “Chapter 691- Bone Structure, Growth, and Hormonal
Regulation.” Behrman: Nelson Textbook of Pediatrics, 17th Ed. Elsevier Saunders 2004.
8. DiVasta AD, Gordon CM. Bone Health in Adolescents. Adolescent Medicine Clinics
2006; 17: 639-652.
9. Unal E, Abaci A, Bober E, Buyukgebiz A. Efficacy and safety of oral alendronate
treatment in children and adolescents with osteoporosis. Journal of Pediatric
Endocrinology and Metabolism 2006 Apr; 19 (4): 523-8.
10. Loud KJ, Gordon CM. Adolescent Bone Health. Arch Pediatr Adolesc Med. 2006;
160: 1026-1032.
11. Ott, Susan M. Editorial: Long-Term Safety of Bisphosphonates. Journal of Clinical
Endocrinology and Metabolism 2005 Mar; 90 (3): 1897-9.
12. Di Leo G, Neri E, Ventura A. Using pamidronate for osteoporosis. The Journal of
Pediatrics 2004 May; 144 (5): 689-90.
13. Henderson, Richard. Low doses of pamidronate for the treatment of osteopenia in
non-ambulatory children. Developmental Medicine & Child Neurology 2006; 48: 708.

Page 15 of 18

Loucks
14. Bachrach LK, Gandrud LM. When to use bisphosphonates. The Journal of Pediatrics
2004 Feb: 144 (2): 285.
15. Szalay EA, Hariman D. Adapting Pediatric DXA Scanning to Clinical Orthopaedics.
Journal of Pediatric Orthopaedics 2006; 26 (5): 686-690.
16. Khan AA, et al. Standards and Guidelines for Performing Central Dual-Energy XRay Absorptiometry in Premonopausal Women, Men, and Children. Journal of Clinical
Densitometry 2004; 7 (1): 51-63.
17. Sholas M, Tann B, Gaebler-Spira D. Oral Bisphosphonates to Treat Disuse
Osteopenia in Children With Disabilities: A Case Series. Journal of Pediatric
Orthopaedics 2005; 25 (3): 326-331.

Page 16 of 18

Loucks
TABLES
Table 1. Comparison of Treatment and Control Groups
Treatment Group
11.9, (2-21)
Avg Age, yrs (range)
Male: 56%, (20/36)
Gender
Female: 44%, (16/36)
14.5, (0.5-53)
Avg Treatment Length,
months (range)
16, (4-42)
Avg Interval between
DXA scan, months (range)
Yes: 36.1%, (13/36)
Ambulatory Status
No: 55.6%, (20/36)
Minimal: 8.3%, (3/36)
69.4%, (25/36)
% With Pathologic
Fracture, (#)
41.7%, (15/36)
% With Gastric Tube, (#)
55.6%, (20/36)
% With Calcium
supplementation, (#)
2.8%, (8/36)
% With Vit. D
supplementation, (#)
63.9%, (23/36)
% Taking Multivitamin
supplementation, (#)
36.1%, (13/36)
% Taking other dietary
supplementation, (#)

Control Group
9.2, (1-16)
Male: 57%, (17/30)
Female: 43%, (13/30)
N/A
17.9, (6-44)
Yes: 63.3%, (19/30)
No: 33.3%, (10/30)
Minimal: 3.3%, (1/30)
13.3%, (4/30)
20%, (6/30)
70%, (21/30)
26.7%, (8/30)
53.3%, (16/30)
53.3%, (16/30)

Table 2. Included Patient’s Medical Histories, # of patients
Treatment Group*
Control Group**
3
3
Cerebral Palsy
3
3
Seizure Disorder
8
6
Cerebral Palsy with
Seizure Disorder
7
7
Osteogenesis Imperfecta
and other Dysplastic
syndromes
6
2
Paralysis
4
11
Corticosteroid therapy or
Malignant Processes
6
2
Other
*Sum of patients is 37; one patient was included in both the CP and paralysis group
**Sum of patients is 34; 1 patient is both seizure and autoimmune, 1 patient is seizure
and other, 1 patient is CP and paralysis, and 1 is both autoimmune and dysplasia.
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Table 3. Results
DXA Region
Mean Mean Treatment
Avg %
Mean Mean Control Avg %
PPre
Post
Change Pre
Post Group*, Change- value
Group*,
BMD BMD
g/cm2
Treatment BMD BMD
g/cm2
Control
0.533 0.625
0.091
18.9%
0.495 0.527
0.032
6.7%
Lumbar
0.03
0.574 0.603
0.029
4.3%
0.529 0.550
0.020
4.6%
0.75
L Hip
0.618 0.697
0.079
12.8%
0.541 0.579
0.038
7.5%
0.15
R Hip
0.047
13.5%
0.520 0.546
0.026
4.8%
0.46
L Femur - R1 0.478 0.525
0.033
9.0%
0.575 0.604
0.028
7.6%
0.77
L Femur– R2 0.482 0.515
0.056
10.7%
0.632 0.713
0.080
22.6%
0.56
L Femur – R3 0.566 0.622
0.067
21.3%
0.522 0.515
-0.007
-2.6%
0.09
R Femur – R1 0.428 0.495
0.034
8.8%
0.577 0.604
0.027
6.2%
0.50
R Femur – R2 0.472 0.505
0.030
5.3%
0.699 0.733
0.034
5.2%
0.92
R Femur – R3 0.569 0.599
*Values presented are the mean values of the difference of BMD in each group.
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